{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.Clinicalstudies.in/SOP-for-Vulnerable-Populations-and-Witness-Consent”
},
“headline”: “SOP for Vulnerable Populations and Witness Consent in Clinical Trials”,
“description”: “This SOP provides a detailed regulatory framework for obtaining consent from vulnerable populations, including the use of impartial witnesses, in compliance with ICH GCP, FDA, EMA, WHO, and CDSCO guidelines.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}
Published on 21/12/2025
Standard Operating Procedure for Vulnerable Populations and Witness Consent
| Department | Clinical Research |
| SOP No. | CR/ICF/013/2025 |
| Supersedes | NA |
| Page No. | 1 of 23 |
| Issue Date | 26/08/2025 |
| Effective Date | 01/09/2025 |
| Review Date | 01/09/2026 |
Purpose
The purpose of this SOP is to define standardized procedures for obtaining informed consent from vulnerable populations, including illiterate participants, children, cognitively impaired individuals, and others
Scope
This SOP applies to all clinical trial staff, investigators, regulatory affairs personnel, and ethics committee members responsible for the enrollment of vulnerable participants in clinical trials. It covers the consent process, documentation, witness responsibilities, and special considerations for various vulnerable groups.
Responsibilities
- Principal Investigator (PI): Ensures consent of vulnerable participants is obtained per regulatory and ethical requirements.
- Study Coordinator/Sub-Investigator: Assists with explanation of study procedures to participants or their legally authorized representatives.
- Impartial Witness: Confirms accurate explanation of study details and voluntary consent of participants unable to read or write.
- Quality Assurance Officer: Verifies compliance of records and witness signatures.
- Head of Clinical Research: Provides oversight and ensures safeguards are implemented.
Accountability
The Principal Investigator is accountable for ensuring that vulnerable participants are included in clinical trials only when justified and that additional protective measures, including the use of witnesses, are implemented and documented.
Procedure
1. Identification of Vulnerable Populations
Vulnerable participants include minors, illiterate individuals, the elderly, mentally impaired, economically disadvantaged, and pregnant women (where applicable).
Confirm eligibility with EC/IRB approval before recruitment.
2. Consent from Legally Authorized Representatives (LAR)
When participants are unable to provide informed consent, obtain consent from a legally authorized representative.
Ensure that the LAR receives the same information as the participant would have been provided.
3. Use of Impartial Witness
An impartial witness must be present for illiterate participants during the entire consent discussion.
The witness signs the ICF after confirming the participant’s verbal consent and fingerprint/thumb impression.
Witness cannot be part of the trial team or sponsor.
4. Documentation
Record participant’s fingerprint/thumb impression, witness signature, and investigator signature.
File original ICF in the trial records and provide a copy to the participant/LAR.
5. Special Safeguards
Ensure simplified language is used for vulnerable groups.
Provide translations where necessary.
Allow sufficient time for questions and discussions.
6. Ongoing Oversight
Monitor the consent process through audits.
Re-consent participants if new information arises that affects risk-benefit assessment.
Abbreviations
- SOP: Standard Operating Procedure
- PI: Principal Investigator
- ICF: Informed Consent Form
- LAR: Legally Authorized Representative
- EC: Ethics Committee
- IRB: Institutional Review Board
- QA: Quality Assurance
Documents
- Witness Consent Template (Annexure-1)
- Vulnerable Participant Consent Log (Annexure-2)
- EC/IRB Approval Letter for Vulnerable Enrollment (Annexure-3)
References
- ICH E6(R2) Good Clinical Practice
- US FDA – Informed Consent Regulations
- EMA Clinical Trial Regulation (EU No. 536/2014)
- WHO Guidelines on Ethics Committees
- CDSCO Clinical Trial Rules, 2019
Version: 1.0
Approval Section
| Prepared By | Rajesh Kumar, Clinical Research Coordinator |
| Checked By | Sunita Reddy, QA Officer |
| Approved By | Dr. Anil Sharma, Principal Investigator |
Annexures
Annexure-1: Witness Consent Template
| Participant ID | Witness Name | Signature | Date |
|---|---|---|---|
| PAT-021 | Ravi Kumar | Signed | 10/09/2025 |
Annexure-2: Vulnerable Participant Consent Log
| Date | Participant ID | Consent Type | Witness | Investigator |
|---|---|---|---|---|
| 12/09/2025 | PAT-025 | Thumb Impression | Ravi Kumar | Dr. Meera Joshi |
Annexure-3: EC/IRB Approval Letter for Vulnerable Enrollment
| Date | EC/IRB Name | Protocol No. | Status | Remarks |
|---|---|---|---|---|
| 08/09/2025 | Metro EC | CTP-2025-08 | Approved | Enrollment of illiterate participants allowed with witness |
Revision History
| Revision Date | Revision No. | Revision Details | Reason for Revision | Approved By |
|---|---|---|---|---|
| 26/08/2025 | 00 | Initial version | New SOP creation | Head, Clinical Research |
For more SOPs visit: Pharma SOP